

Kyung-Sang Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7622573/publications.pdf>

Version: 2024-02-01

121
papers

1,955
citations

304368

22
h-index

315357

38
g-index

122
all docs

122
docs citations

122
times ranked

2593
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for <i>Helicobacter pylori</i> eradication. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 138-144.	1.1	18
2	Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-Japanese. <i>Clinical and Translational Science</i> , 2022, 15, 490-500.	1.5	4
3	Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G-CSF, in Pediatric Patients with Solid Tumors. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 293-301.	2.3	1
4	Cytoplasmic zinc promotes IL-1 β production by monocytes and macrophages through mTORC1-induced glycolysis in rheumatoid arthritis. <i>Science Signaling</i> , 2022, 15, eabi7400.	1.6	16
5	Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3288-3296.	1.1	33
6	Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter 2 inhibitor, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4100-4110.	1.1	14
7	Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension. <i>Scientific Reports</i> , 2022, 12, 7393.	1.6	6
8	Optimization and validation of a fluorogenic dipeptidyl peptidase 4 enzymatic assay in human plasma. <i>Analytical Biochemistry</i> , 2021, 612, 113952.	1.1	0
9	Effects of peramppanel on cognition and quantitative electroencephalography in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 115, 107514.	0.9	13
10	Tolerability of lacosamide rapid dose titration: A randomized, multicenter, prospective, open-label study. <i>Epilepsy and Behavior</i> , 2021, 115, 107663.	0.9	5
11	The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 36, 100368.	1.1	8
12	Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 53.	0.3	1
13	Comprehensive analysis of important pharmacogenes in Koreans using the DMET platform. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 135.	0.3	3
14	Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 45.	0.3	1
15	Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 651-658.	2.0	0
16	Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 36, 100374.	1.1	4
17	Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESPÂ®) Biosimilar, to Those of NESPÂ® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1735-1747.	2.0	1
18	Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019. <i>Frontiers in Pharmacology</i> , 2021, 12, 651790.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects. <i>Clinical and Translational Science</i> , 2021, 14, 1955-1966.	1.5	10
20	Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2375-2384.	2.0	1
21	The necessary conduct: Exploratory multiregional clinical trials in East Asia. <i>Clinical and Translational Science</i> , 2021, 14, 2399-2407.	1.5	5
22	Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108985.	1.1	20
23	A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 6.	0.3	4
24	Trends of clinical trials from 2017 to 2019 in Korea: an integrated analysis based on the Ministry of Food and Drug Safety (MFDS) and the Clinical Research Information Service (CRIS) registries. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 186.	0.3	2
25	Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 5099-5108.	2.0	6
26	Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 923-932.	1.1	5
27	<p>Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5179-5187.	2.0	2
28	<p>Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1953-1961.	2.0	6
29	Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects. <i>Clinical Therapeutics</i> , 2020, 42, 1946-1954.e2.	1.1	2
30	Usefulness of saliva for perampanel therapeutic drug monitoring. <i>Epilepsia</i> , 2020, 61, 1120-1128.	2.6	15
31	Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers. <i>Pharmacogenomics Journal</i> , 2020, 20, 792-800.	0.9	7
32	An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men. <i>Clinical Therapeutics</i> , 2020, 42, 1047-1057.	1.1	6
33	Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1640-1647.	1.9	24
34	Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects. <i>Translational and Clinical Pharmacology</i> , 2020, 28, 43.	0.3	2
35	The Impact of COVID-19 on the Conduct of Clinical Trials for Medical Products in Korea. <i>Journal of Korean Medical Science</i> , 2020, 35, e329.	1.1	14
36	Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers. <i>Translational and Clinical Pharmacology</i> , 2020, 28, 181.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes. <i>Translational and Clinical Pharmacology</i> , 2020, 28, 199.	0.3	0
38	Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 284-292.	1.3	8
39	<p><p>Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects<p><p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2533-2542.	2.0	5
40	Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis. <i>Cancers</i> , 2019, 11, 1497.	1.7	63
41	Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 247-252.	1.1	14
42	Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways. <i>Metabolomics</i> , 2019, 15, 30.	1.4	16
43	Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	5
44	A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 227.	1.0	13
45	Pharmacokinetic comparison between fixed-dose combination of fimasartan/amlodipine 60/10 mg and the corresponding loose combination through partial replicated crossover study in healthy subjects. <i>Translational and Clinical Pharmacology</i> , 2019, 27, 134.	0.3	1
46	<p><p>A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects<p><p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3879-3885.	2.0	3
47	Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment. <i>Translational and Clinical Pharmacology</i> , 2019, 27, 107.	0.3	10
48	The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	18
49	Identification of ð%â€•or (ð%â€•)â€•Hydroxylated Mediumâ€•Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 879-887.	2.3	10
50	Assessment of Appropriateness of an Initial Dosing Regimen of Vancomycin and Development of a New Dosing Nomogram. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 233-238.	1.2	6
51	Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 115-119.	1.0	5
52	Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity. <i>Genomics and Informatics</i> , 2018, 16, 52-58.	0.4	8
53	Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment. <i>Journal of Korean Medical Science</i> , 2018, 33, e298.	1.1	8
54	Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 16.	0.3	5

#	ARTICLE	IF	CITATIONS
55	Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2018, 40, 1720-1728.e2.	1.1	6
56	Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials. <i>Pharmaceutical Research</i> , 2018, 35, 236.	1.7	3
57	Assessment of induced CYP3A activity in pregnant women using 4 β -hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 173-178.	1.1	17
58	Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2301-2309.	2.0	5
59	Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 787-794.	2.0	4
60	Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. <i>Scientific Reports</i> , 2018, 8, 11874.	1.6	54
61	Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	122
62	Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females. <i>AAPS Journal</i> , 2017, 19, 1196-1204.	2.2	24
63	LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects. <i>BioDrugs</i> , 2017, 31, 349-355.	2.2	9
64	A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 619-624.	1.9	7
65	Pharmacokinetics and safety of a single dose of the novel necrosis inhibitor LC28 α 126 in healthy male subjects. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1205-1215.	1.1	7
66	Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects. <i>Clinical Therapeutics</i> , 2017, 39, 1849-1857.	1.1	7
67	Reliable prediction of anti-diabetic drug failure using a reject option. <i>Pattern Analysis and Applications</i> , 2017, 20, 883-891.	3.1	8
68	Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229). <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 294-298.	2.2	13
69	Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 713-723.	2.0	7
70	Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies. <i>Infection and Chemotherapy</i> , 2017, 49, 135.	1.0	8
71	Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon [®] and Eprex [®] following a single subcutaneous administration in healthy male volunteers. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3127-3135.	2.0	7
72	A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3171-3177.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 4005-4016.	2.0	26
74	Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2525-2534.	2.0	12
75	Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 106-110.	1.1	14
76	Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5033.	2.0	9
77	A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2609.	2.0	21
78	A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2015, 9, 729.	2.0	7
79	Successful Empirical Antifungal Therapy of Intravenous Itraconazole with Pharmacokinetic Evidence in Pediatric Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Drug Investigation</i> , 2015, 35, 437-446.	1.1	8
80	An efficient and effective ensemble of support vector machines for anti-diabetic drug failure prediction. <i>Expert Systems With Applications</i> , 2015, 42, 4265-4273.	4.4	41
81	Validated LC-MS/MS Assay for the Quantitative Determination of Fimasartan in Human Plasma: Application to Pharmacokinetic Studies. <i>Journal of Chromatographic Science</i> , 2015, 53, 1250-1256.	0.7	5
82	Pharmacokinetic Properties and Tolerability of Rotigotine Transdermal Patch After Repeated-Dose Application in Healthy Korean Volunteers. <i>Clinical Therapeutics</i> , 2015, 37, 902-912.	1.1	10
83	Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. <i>Oncologist</i> , 2015, 20, 896-897.	1.9	17
84	Favorable Outcome of Hematopoietic Stem Cell Transplantation Using a Targeted Once-Daily Intravenous Busulfan-Fludarabine-Etoposide Regimen in Pediatric and Infant Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 190-195.	2.0	34
85	Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1723.	2.0	3
86	Seasonal Variation in Hemoglobin A1c in Korean Patients with Type 2 Diabetes Mellitus. <i>Journal of Korean Medical Science</i> , 2014, 29, 550.	1.1	22
87	Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1709.	2.0	43
88	Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry. <i>Annals of Laboratory Medicine</i> , 2014, 34, 7-14.	1.2	26
89	Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 477-485.	0.7	17
90	Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study. <i>Clinical Therapeutics</i> , 2014, 36, 101-114.	1.1	6

#	ARTICLE	IF	CITATIONS
91	An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects. <i>Investigational New Drugs</i> , 2014, 32, 636-643.	1.2	8
92	Pharmacokineticâ€“Pharmacodynamic Relationships of Macitentan, a New Endothelin Receptor Antagonist, After Multiple Dosing in Healthy Korean Subjects. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 377-385.	1.0	11
93	Pharmacodynamics, Pharmacokinetics, and Tolerability of Intravenous or Subcutaneous GC1113, a Novel Erythropoiesis-Stimulating Agent. <i>Clinical Drug Investigation</i> , 2014, 34, 373-382.	1.1	3
94	Pharmacokinetic and Pharmacodynamic Interaction Between Gemigliptin and Metformin in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2014, 34, 383-393.	1.1	18
95	Sustained Increase in the Oral Bioavailability of Loperamide after a Single Oral Dose of HM30181, a P-glycoprotein Inhibitor, in Healthy Male Participants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 419-424.	1.2	14
96	Relationship Between Absolute Neutrophil Count Profiles and Pharmacokinetics of DA-3031, a Pegylated Granulocyte Colony-Stimulating Factor (Pegylated-G-CSF): A Dose Block-Randomized, Double-Blind, Dose-Escalation Study in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 817-824.	1.1	8
97	Pharmacokinetic and Pharmacodynamic Properties of a New Long-Acting Granulocyte Colony-Stimulating Factor (HM10460A) in Healthy Volunteers. <i>BioDrugs</i> , 2013, 27, 149-158.	2.2	6
98	Increased Systemic Exposure of Fimasartan, an Angiotensin II Receptor Antagonist, by Ketoconazole and Rifampicin. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 75-81.	1.0	28
99	A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 162-172.	0.8	3
100	Global Metabolomics and Targeted Steroid Profiling Reveal That Rifampin, a Strong Human PXR Activator, Alters Endogenous Urinary Steroid Markers. <i>Journal of Proteome Research</i> , 2013, 12, 1359-1368.	1.8	23
101	Pharmacokineticâ€“Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 113-125.	1.2	8
102	Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 195-203.	1.0	80
103	Assessment of the Drugâ€“Drug Interactions Between Fimasartan and Hydrochlorothiazide in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 84-91.	0.8	21
104	Comparative Pharmacokinetics/Pharmacodynamics of Clopidogrel Besylate and Clopidogrel Bisulfate in Healthy Korean Subjects. <i>Clinical Drug Investigation</i> , 2012, 32, 817-826.	1.1	4
105	Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. <i>Current Medical Research and Opinion</i> , 2012, 28, 1213-1220.	0.9	14
106	Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®). <i>BioDrugs</i> , 2012, 26, 177-184.	2.2	30
107	Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination of Optimal Once-Daily Busulfan Dose Using Pharmacokinetic Modeling. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 944-950.	2.0	53
108	The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2012, 55, 1080-1087.	2.9	335

#	ARTICLE	IF	CITATIONS
109	Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human Study. <i>Clinical Therapeutics</i> , 2012, 34, 1986-1998.	1.1	24
110	Assessment of the Analgesic Effect of Remifentanyl using Three Pain Models in Healthy Korean Volunteers: A Randomized, Controlled Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 518-523.	1.2	2
111	The Effect of the Newly Developed Angiotensin Receptor II Antagonist Fimasartan on the Pharmacokinetics of Atorvastatin in Relation to OATP1B1 in Healthy Male Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 492-499.	0.8	29
112	Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 682-689.	0.8	44
113	Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 307-310.	1.1	8
114	Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 883-890.	1.1	35
115	Effect of Cytochrome P450 2C19 Genetic Polymorphism and Coadministration with Ketoconazole on the Platelet Aggregation Response to Clopidogrel in Korean Healthy Subjects. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2009, 17, 51.	0.1	0
116	Pharmacokinetics of Irsogladin Maleate in Healthy Korean Volunteers. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2009, 17, 35.	0.1	0
117	Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose- and block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study. <i>Clinical Therapeutics</i> , 2008, 30, 1817-1830.	1.1	41
118	Bioequivalence study of S-amlodipine Gentisate Conventional Versus new Formulation. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2008, 16, 37.	0.1	0
119	Population Pharmacokinetics of Vancomycin in Korean Pediatric Patients. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2008, 16, 21.	0.1	0
120	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Potassium Channel Opener, SKP-450, in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 752-761.	1.0	4
121	Population Pharmacokinetics of Vancomycin in Korean Patients. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 1998, 6, 142.	0.1	0